Compare TG Therapeutics Inc (TGTX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vistra Corp — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vistra Corp trades at $161.48 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 6.4× TG Therapeutics Inc's market cap, and Vistra Corp pays a 0.59% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vistra Corp for 32 Days on average.
| TGTX | VST | |
|---|---|---|
Market Cap | $8.16B | $52.41B |
Volume | 1,735,121 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $59.06 | $210.85 |
52-Week Low | $26.94 | $134.71 |
Typical Hold Time | 16 Days | 32 Days |
Enterprise Value | $8.37B | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Vistra Corp. (VST) trades at $156.14, down 6.35% over 24 hours amid mixed earnings history, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Technical indicators show a bullish trend with support at $152 and resistance at $164, while fundamentals highlight strong profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan for nuclear power expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Outlook remains positive with a consensus price target of $215.23 (38% upside), supported by analyst bullishness (91.3% buy ratings) and institutional interest. Key risks include execution on nuclear projects, debt levels, and volatile earnings. The stock offers exposure to the AI power scarcity theme, but investors should monitor Q3 2026 results on November 6 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
